CINECA IRIS Institutional Research Information System

ARENA, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.580
EU - Europa 4.177
AS - Asia 3.024
SA - Sud America 257
OC - Oceania 92
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.290
CN - Cina 1.634
IT - Italia 1.602
DE - Germania 404
GB - Regno Unito 364
JP - Giappone 314
FR - Francia 302
IE - Irlanda 218
ES - Italia 182
CA - Canada 173
KR - Corea 163
PL - Polonia 157
FI - Finlandia 144
SE - Svezia 139
TW - Taiwan 123
TR - Turchia 122
IN - India 120
UA - Ucraina 116
HK - Hong Kong 97
MX - Messico 94
NL - Olanda 80
BE - Belgio 78
SG - Singapore 77
CH - Svizzera 75
VN - Vietnam 68
BR - Brasile 65
AU - Australia 64
PE - Perù 60
AT - Austria 56
IL - Israele 55
TH - Thailandia 42
CO - Colombia 38
CZ - Repubblica Ceca 34
RO - Romania 34
CL - Cile 33
GR - Grecia 33
SA - Arabia Saudita 30
IR - Iran 29
DK - Danimarca 28
ID - Indonesia 28
NZ - Nuova Zelanda 28
PT - Portogallo 26
HU - Ungheria 24
AR - Argentina 21
EC - Ecuador 21
MY - Malesia 16
RU - Federazione Russa 16
LB - Libano 15
NO - Norvegia 15
SN - Senegal 15
JO - Giordania 13
SK - Slovacchia (Repubblica Slovacca) 13
PH - Filippine 12
GY - Guiana 10
NG - Nigeria 10
PS - Palestinian Territory 10
KZ - Kazakistan 9
PR - Porto Rico 9
EG - Egitto 8
MO - Macao, regione amministrativa speciale della Cina 8
AE - Emirati Arabi Uniti 7
AM - Armenia 7
LV - Lettonia 7
NI - Nicaragua 6
HR - Croazia 5
QA - Qatar 5
UZ - Uzbekistan 5
BY - Bielorussia 4
LT - Lituania 4
RS - Serbia 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
CY - Cipro 3
IQ - Iraq 3
PK - Pakistan 3
SI - Slovenia 3
TN - Tunisia 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AP - ???statistics.table.value.countryCode.AP??? 2
BO - Bolivia 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
IS - Islanda 2
MN - Mongolia 2
SV - El Salvador 2
TZ - Tanzania 2
ZA - Sudafrica 2
AL - Albania 1
CU - Cuba 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
LK - Sri Lanka 1
MA - Marocco 1
PA - Panama 1
SY - Repubblica araba siriana 1
Totale 13.179
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.134
Chandler 352
Beijing 343
Fairfield 227
Redwood City 220
Shanghai 210
Dublin 195
Houston 181
Guangzhou 161
Torino 145
Ashburn 136
Dearborn 135
Turin 133
Woodbridge 126
Milan 118
Cambridge 109
Wilmington 109
Seattle 90
Tokyo 80
Villeurbanne 71
Rome 65
Jacksonville 63
Lappeenranta 62
New York 60
Princeton 60
Nanjing 59
Nyköping 59
Warsaw 59
Hangzhou 58
Medford 55
Fremont 51
Taipei 51
Boston 47
Lima 47
Pisa 44
Wuhan 44
Vienna 42
Buffalo 40
Dundee 39
Brussels 38
Genoa 38
Carrara 36
Paris 36
San Diego 36
Seoul 35
Dong Ket 34
London 34
Toronto 34
Barcelona 32
Istanbul 32
Chengdu 31
Stuttgart 30
Duncan 29
Ithaca 28
Bologna 27
Chongqing 26
Jinan 26
Ottawa 26
Berlin 25
Norwalk 25
Kunming 24
Singapore 24
Los Angeles 23
Shenyang 23
Zhengzhou 22
Chicago 21
Luni 21
Madrid 21
Iowa City 20
Munich 20
Tianjin 20
Washington 20
Brooklyn 19
Phoenix 19
Sydney 19
Xian 19
Zurich 19
Bogotá 18
Florence 18
Santiago 18
Central District 17
Marcellus 17
Naples 17
Bangkok 16
Central 16
Toulouse 16
Changsha 15
Shenzhen 15
Medellín 14
Nanchang 14
Pittsburgh 14
San Francisco 14
Amsterdam 13
Bucharest 13
Bursa 13
Hong Kong 13
Jerusalem 13
Miami 13
Portland 13
Valencia 13
Totale 6.635
Salva come PNG Salva come JPEG
Nome #
High-dose Vitamin C enhances cancer immunotherapy 4.000
Adaptive mutability of colorectal cancers in response to targeted therapies 1.621
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.112
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 545
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 447
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 416
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 401
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 317
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 277
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 254
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 189
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 186
Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer 182
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 165
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance 136
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers 135
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES 128
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 123
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 123
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 115
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. 108
The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. 107
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer 107
Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1 105
Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes. 103
EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES 102
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 101
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 98
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 97
Expression and Functional Regulation of Myoglobin in Epithelial Cancers 96
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells 94
Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells 92
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses 91
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer 90
Understanding how kinase-targeted therapies work 87
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 77
Genetic analysis of the kinome and phosphatome in cancer 76
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 76
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET 75
Identification of cancer genes by mutational profiling of tumor genomes 70
Genetic targeting of the kinase activity of the Met receptor in cancer cells 70
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells 69
PIK3CA cancer mutations display gender and tissue specificity patterns 68
Isogenic mutant human cells: a new tool for personalized cancer medicine 64
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer 62
Targeted Knock-in of the Polymorphism rs61764370 Does Not Affect KRAS Expression but Reduces let-7 Levels 61
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids 52
Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges 46
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study 39
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors 37
Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells 30
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) 29
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities 28
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells 26
“METODO PER PREDIRE LA SENSIBILITA’ A UN CHEMIOTERAPICO O AD UN FARMACO INIBITORE DELLA RISPOSTA AL DANNO AL DNA DI UN INDIVIDUO AFFETTO DA TUMORE” "METHOD FOR PREDICTING SENSITIVITY TO CHEMOTHERAPEUTIC AGENTS and DRUGS TARGETING THE DNA DAMAGE RESPONSE PATHWAY IN A TUMOUR AFFECTED INDIVIDUAL" 18
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient 11
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells 6
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer 3
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer 2
Totale 13.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.781
article - articoli 0
book - libri 0
conference - conferenze 990
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.771
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019188 0 0 0 0 0 0 0 0 0 0 131 57
2019/2020963 63 42 42 98 71 127 112 58 88 99 101 62
2020/20212.397 53 101 251 239 184 216 305 151 204 197 145 351
2021/20223.407 365 421 359 435 217 191 248 219 261 176 268 247
2022/20232.826 210 191 254 234 201 350 246 236 293 160 272 179
2023/20242.246 255 225 234 225 222 195 159 194 80 306 151 0
Totale 13.445